Am­i­cus and Per­cep­tive call off SPAC merg­er for gene ther­a­py spin­out af­ter re­cent set­back

Rough­ly a month af­ter Am­i­cus Ther­a­peu­tics re­port­ed an un­ex­pect­ed set­back in a gene ther­a­py planned to be spun out in a SPAC deal, the biotech and its blank check part­ner have called off the merg­er — the sec­ond high-pro­file SPAC de­cou­pling in re­cent months.

Am­i­cus will not spin out its gene ther­a­py unit with Arya Sci­ences Ac­qui­si­tion IV, the fourth SPAC be­long­ing to Joseph Edel­man’s Per­cep­tive, af­ter all. The two say they have mu­tu­al­ly agreed to end merg­er dis­cus­sions, leav­ing Edel­man with about an­oth­er year to find a part­ner to take pub­lic.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN